Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray, Inc. is a cannabis and consumer packaged goods company with more than 20 brands, offering cannabis offerings, hemp-based foods, and alcoholic beverages.

Tilray's DCF: Aphria, MedMen, And More Innovation Mean Upside Potential

OrganiGram Holdings Inc.

2 Marijuana Stocks To End The First Week Of October The post 2 Marijuana Stocks To Watch To Close Out The Week appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stocks To Watch To Close Out The Week

Agrify

Cannabis Growth ETF

Canopy Growth

Clever Leaves Holdings Inc

Flora Growth Corp

HEXO Corp

High Tide

Akerna Corp

Molson Coors Brewing

Urban-gro

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

This Week in Cannabis Stocks: Cannabis ETF Launches

On Thursday, Tilray, Inc. (NASDAQ:TLRY) (TSX:TLRY) released its financial results for the first fiscal quarter ended August 31, 2021, revealing net revenue of $168 million, up by 43% year-over-year and below the consensus estimates of $174.93 million. Based in New York and Ontario, the company attributed the revenue growth to a 38% improvement in net cannabis revenue to $70 million, net beverage alcohol revenue of $15 million following the SweetWater acquisition, and revenue of $15 million from Manitoba Harvest.

What Investors Need To Know On Heels Of Tilray's Q1 Earnings Release

General Motors

Arrival Group

Levi Strauss

Tilray, Arrival, General Motors and Levi were our top stock trades for Friday. So let's have a look at what the charts suggest now.

4 Top Stock Trades for Friday: TLRY, ARVL, GM, LEVI

SNDL Inc.

One high-ranking federal banking insider calls marijuana legalization "a foregone conclusion."

Why Hexo, Tilray, Canopy Growth, and Sundial Stocks Are Glowing Green Today

GrowGeneration Corp

Charlottes Web Holdings (OTC:CWBHF) shares closed up 21.59% at $2.14 with an estimated market cap of $271.7M. CURE Pharmaceutical Hldg (OTC:CURR) shares closed up 15.86% at $0.65 with an estimated market cap of $40.9M.

Bullish Sentiment For Marijuana Stocks: Tilray, GrowGeneration & Canopy Growth Among Top Cannabis Movers For October 7, 2021

Irwin Simon, CEO of Canada-based cannabis company Tilray (NASDAQ:TLRY), said Thursday on CNBC that the company intends to drive growth by building its medical business and potential M&A. The M&A approach to growth, Simon noted, can fast-track the process because it allows Tilray to skip the hassles of building a business from scratch, wrote SeekingAlpha.

Tilray CEO: Expand The Company's Medical Cannabis Business, 'Opportunities Are Tremendous'

Tilray Inc. (NASDAQ:TLRY) shares ended Thursday's session higher in a reversal after the cannabis company posted worse-than-expected earnings. The company said its first-quarter net loss increased to $34.6 million, or 8 cents per share, from a loss of $21.7 million, or 9 cents per share, from the year ago period.

Tilray Stock Breaks Below Pattern: What's Next For The Cannabis Stock?

More big names in cannabis are switching to psychedelics. Greg Engel, former CEO of Tilray (NASDAQ:TLRY) and Organigram Holdings (NASDAQ:OGI) has become the latest cannabis veteran to join the psychedelics industry, taking on the role of director at Clairvoyant Therapeutics.

Former Tilray CEO Joins Psychedelics Company

On Thursday, Tilray Inc. (NASDAQ:TLRY) shares surged nearly 4% after announcing its most recent quarterly results. The company reported its fiscal Q1 revenue and earnings before markets opened, missing analyst expectations.

Is Tilray stock a buy or sell after missing FQ1 expectations?

Tilray, Inc. (TLRY) CEO Irwin Simon on Q1 Fiscal 2022 Results - Earnings Call Transcript

Aurora Cannabis

Despite disappointing earnings results from Tilray, cannabis stocks are on the move higher. Here's what investors should know.

TLRY, SNDL, CGC, ACB: What Is Going on With Cannabis Stocks Today?

Cronos Group

Federal Regulators Urge Congress To Pass The SAFE Banking Act The post Federal Regulators Want Congress To Pass Cannabis Banking Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Federal Regulators Want Congress To Pass Cannabis Banking Now

Shares of Tilray Inc. rose on Thursday despite a wider-than-expected loss from the Canadian cannabis producer, as the company reported a jump in sales despite pressures from the COVID pandemic.

Cannabis Watch: Tilray shares climb as investors shrug off revenue miss and bigger-than-expected loss

Today, Benzinga‘s options scanner spotted 19 uncommon options trades for Tilray. The overall sentiment shows 36.84% of the big-money traders are bullish on the stock and 63.16%, bearish.

This Is What Smart Money Is Betting On Tilray

The shares of Canadian pot producer Tilray Inc (NASDAQ:TLRY) are down 1.8% to trade at $10.60 this morning, after the company's fiscal first-quarter revenue fell short of analysts' estimates, despite jumping 43% year-over-year thanks to strong demand for weed products following pandemic-related lockdowns.

Pot Stock Takes a Breather After Revenue Miss

Canadian cannabis giant Tilray, Inc. (NASDAQ:TLRY) (TSX:TLRY) released its financial results Thursday for the first fiscal quarter ended August 31, 2021, with net revenue of $168 million, up by 43% from $117 million in the same period of fiscal 2021.  Reported revenues were below the consensus estimates of $174.93 million.

Tilray's Q1 Revenue Grows 43% To $168M, Achieves 10th Consecutive Quarter Of Positive Adjusted EBITDA

Tilray Inc (NASDAQ: TLRY) has reported Q1 FY22 sales of $168 million, +43% Y/Y, missing the consensus of $172.6 million. The increase was driven by a 38% Y/Y growth in net cannabis revenue to $70 million.

Tilray Clocks 43% Sales Growth In Q1

Tilray Inc. TLRY, -2.79% said Thursday its first quarter net loss widened to $34.6 million or 8 cents a share, from a loss of $21.7 million, or 9 cents a share in the year-ago period. The cannabis company said sales increased to $168 million from $117.5 million.

Tilray posts larger-than-expected loss

Canadian pot producer Tilray Inc on Thursday reported a 43% rise in first-quarter revenue, driven by strong demand for cannabis after coronavirus-led lockdowns.

Tilray posts 43% rise in quarterly revenue on strong cannabis demand

NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for the first fiscal quarter ended August 31, 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated, and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”). Irwin D. Simon, Tilray'

Tilray, Inc. Reports First Quarter Fiscal Year 2022 Financial Results

Canadian cannabis giant Tilray Inc.'s (NASDAQ:TLRY) (TSX:TLRY) CEO Irwin Simon has received nearly $30 million in total compensation so far in calendar 2021, with nearly half of that sum paid in cash, according to a recently disclosed regulatory filing. The compensation paid to the CEO includes cash bonuses totaling $13.2 million, in addition to a salary raise and millions he received in share-based awards, Marijuana Business Daily writes.

Tilray CEO Received Nearly $30M In Compensation In Calendar 2021, $13.2M In Cash Bonuses...So Far

Conagra Brands

There was just one earnings report of note Tuesday morning, and while PepsiCo beat on both the top and bottom lines, earnings guidance for the fiscal year did not quite meet estimates, leaving the stock with a small gain in early trading.

Earnings Previews: Conagra Brands, Levi Strauss, Tilray

TLRY stock has no realistic path toward increased revenues and stock price. The $4 billion goal doesn't appear achievable.

News for Tilray Brands Stock (TLRY)